Item 8.01. Other Events.
On September 26, 2012, Endo Pharmaceuticals Inc., a subsidiary of Endo Health
Solutions Inc., announced the receipt of Paragraph IV Certification Notices from
both Teva Pharmaceuticals USA, Inc. and Amneal Pharmaceuticals, LCC, each
advising of their respective filings of an Abbreviated New Drug Application
(ANDA) for a generic version of our formulation of OpanaŽ ER (oxymorphone
hydrochloride) extended-release tablets designed to be crush-resistant.
A copy of the press release announcing the receipt of these Paragraph IV
Certification Notices is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired.
Not applicable.
(b) Pro Forma Financial Information.
Not applicable.
(c) Shell Company Transactions.
Not applicable.
(d) Exhibits.
Exhibit Number Description
99.1 Press Release